Cancer is still the most common cause of death for men in the US ages 60 to 79 and women ages 40 to 79. For all adults ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

In this analysis, researchers aimed to evaluate the clinicopathologic characteristics, metastatic patterns, and survival outcomes in patients with metastatic prostate cancer and low-volume primary ...

Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had ...

The American Cancer Society announced that the five-year survival rate for all cancers combined in the U.S. has reached 70% ...

A new American Cancer Society report highlights major improvements in cancer survivorship.About 70% of people in the U.S.

The five-year relative survival for all cancers combined has reached a milestone, according to the American Cancer Society.

For the first time, the five-year relative survival rate for all cancers combined reached 70%, according to the latest report ...

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...

Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients with undetectable PSA levels.

Prostate cancer is the most common cancer in men, with about 1-in-8 expected to be diagnosed in their lifetime.

New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...